420 Investor interviewed OrganiGram CEO Denis Arsenault. The company, which began trading on the TSX Venture exchange on 8/25 (OGI), has a U.S. ticker as well: OGRMF. The interview covered the Canadian MMJ market, OrganiGram's differentiation from its peers, why the company is listing on the OTCQB in the U.S., the patient acquisition strategy, near-term operating metrics, potential capital raises and the possibility of being a consolidator.
For more information on OrganiGram: